Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer

Ritu Salani, Allison Axtell, Melissa Gerardi, Christine Holschneider, Robert E. Bristow

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the predictive value of conventional criteria for identifying surgically unresectable disease among patients with ovarian cancer undergoing initial operative intervention at tertiary referral centers employing a so-called aggressive approach to surgical cytoreduction. Methods: All patients with advanced epithelial ovarian cancer undergoing primary surgery between August 1997 and August 2006 were identified. Surgical/pathological documentation of disease extent pre/post-cytoreduction was extracted from the medical record retrospectively. All patients meeting conventional criteria for unresectable disease criteria (ascites> 1000 mL, omental extension to spleen > 1 cm, parenchymal liver disease > 1cm, porta hepatis involvement > 1 cm, diaphragmatic disease > 1 cm, carcinomatosis > 1 cm, and suprarenal adenopathy > 1 cm) were selected for further study. Results: A total of 180 consecutive patients had disease meeting conventional criteria for unresectability at = 1 site(s). Optimal cytoreduction (residual disease = 1 cm) was achieved in 166 patients (92.2%). Optimal resection rates according to the most common individual unresectable disease criteria were as follows: ascites > 1000 mL = 91.3% (116/127), carcinomatosis > 1 cm = 91.0% (81/89), and splenic involvement > 1 cm = 84.9% (45/53). For patients with ascites > 1000 mL alone, optimal cytoreduction was achieved in 95.8% (46/48) of cases. Optimal resection rates according to the total number of unresectable disease sites were as follows: 1 site = 95.0% (19/20), 2 sites = 93.8% (61/65), 3 sites = 81.5% (22/27), 4 sites = 93.3% (14/15), and 5 sites = 80.0% (4/5). Conclusions: These data suggest that commonly accepted criteria of surgically unresectable disease for women with advanced ovarian cancer lack the necessary precision to guide clinical management. Pre-operative assessment of resectability should be made by an experienced surgical team prior to deferring the initial attempt at surgical cytoreduction.

Original languageEnglish (US)
Pages (from-to)271-275
Number of pages5
JournalGynecologic Oncology
Volume108
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Ascites
Ovarian Neoplasms
Carcinoma
Ovarian epithelial cancer
Tertiary Care Centers
Documentation
Medical Records
Liver Diseases
Spleen

Keywords

  • Cytoreductive surgery
  • Ovarian cancer
  • Unresectable disease

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. / Salani, Ritu; Axtell, Allison; Gerardi, Melissa; Holschneider, Christine; Bristow, Robert E.

In: Gynecologic Oncology, Vol. 108, No. 2, 02.2008, p. 271-275.

Research output: Contribution to journalArticle

Salani, Ritu ; Axtell, Allison ; Gerardi, Melissa ; Holschneider, Christine ; Bristow, Robert E. / Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. In: Gynecologic Oncology. 2008 ; Vol. 108, No. 2. pp. 271-275.
@article{49e961dbc2a3496bb9393abdedbd3780,
title = "Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer",
abstract = "Objective: To evaluate the predictive value of conventional criteria for identifying surgically unresectable disease among patients with ovarian cancer undergoing initial operative intervention at tertiary referral centers employing a so-called aggressive approach to surgical cytoreduction. Methods: All patients with advanced epithelial ovarian cancer undergoing primary surgery between August 1997 and August 2006 were identified. Surgical/pathological documentation of disease extent pre/post-cytoreduction was extracted from the medical record retrospectively. All patients meeting conventional criteria for unresectable disease criteria (ascites> 1000 mL, omental extension to spleen > 1 cm, parenchymal liver disease > 1cm, porta hepatis involvement > 1 cm, diaphragmatic disease > 1 cm, carcinomatosis > 1 cm, and suprarenal adenopathy > 1 cm) were selected for further study. Results: A total of 180 consecutive patients had disease meeting conventional criteria for unresectability at = 1 site(s). Optimal cytoreduction (residual disease = 1 cm) was achieved in 166 patients (92.2{\%}). Optimal resection rates according to the most common individual unresectable disease criteria were as follows: ascites > 1000 mL = 91.3{\%} (116/127), carcinomatosis > 1 cm = 91.0{\%} (81/89), and splenic involvement > 1 cm = 84.9{\%} (45/53). For patients with ascites > 1000 mL alone, optimal cytoreduction was achieved in 95.8{\%} (46/48) of cases. Optimal resection rates according to the total number of unresectable disease sites were as follows: 1 site = 95.0{\%} (19/20), 2 sites = 93.8{\%} (61/65), 3 sites = 81.5{\%} (22/27), 4 sites = 93.3{\%} (14/15), and 5 sites = 80.0{\%} (4/5). Conclusions: These data suggest that commonly accepted criteria of surgically unresectable disease for women with advanced ovarian cancer lack the necessary precision to guide clinical management. Pre-operative assessment of resectability should be made by an experienced surgical team prior to deferring the initial attempt at surgical cytoreduction.",
keywords = "Cytoreductive surgery, Ovarian cancer, Unresectable disease",
author = "Ritu Salani and Allison Axtell and Melissa Gerardi and Christine Holschneider and Bristow, {Robert E.}",
year = "2008",
month = "2",
doi = "10.1016/j.ygyno.2007.11.004",
language = "English (US)",
volume = "108",
pages = "271--275",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer

AU - Salani, Ritu

AU - Axtell, Allison

AU - Gerardi, Melissa

AU - Holschneider, Christine

AU - Bristow, Robert E.

PY - 2008/2

Y1 - 2008/2

N2 - Objective: To evaluate the predictive value of conventional criteria for identifying surgically unresectable disease among patients with ovarian cancer undergoing initial operative intervention at tertiary referral centers employing a so-called aggressive approach to surgical cytoreduction. Methods: All patients with advanced epithelial ovarian cancer undergoing primary surgery between August 1997 and August 2006 were identified. Surgical/pathological documentation of disease extent pre/post-cytoreduction was extracted from the medical record retrospectively. All patients meeting conventional criteria for unresectable disease criteria (ascites> 1000 mL, omental extension to spleen > 1 cm, parenchymal liver disease > 1cm, porta hepatis involvement > 1 cm, diaphragmatic disease > 1 cm, carcinomatosis > 1 cm, and suprarenal adenopathy > 1 cm) were selected for further study. Results: A total of 180 consecutive patients had disease meeting conventional criteria for unresectability at = 1 site(s). Optimal cytoreduction (residual disease = 1 cm) was achieved in 166 patients (92.2%). Optimal resection rates according to the most common individual unresectable disease criteria were as follows: ascites > 1000 mL = 91.3% (116/127), carcinomatosis > 1 cm = 91.0% (81/89), and splenic involvement > 1 cm = 84.9% (45/53). For patients with ascites > 1000 mL alone, optimal cytoreduction was achieved in 95.8% (46/48) of cases. Optimal resection rates according to the total number of unresectable disease sites were as follows: 1 site = 95.0% (19/20), 2 sites = 93.8% (61/65), 3 sites = 81.5% (22/27), 4 sites = 93.3% (14/15), and 5 sites = 80.0% (4/5). Conclusions: These data suggest that commonly accepted criteria of surgically unresectable disease for women with advanced ovarian cancer lack the necessary precision to guide clinical management. Pre-operative assessment of resectability should be made by an experienced surgical team prior to deferring the initial attempt at surgical cytoreduction.

AB - Objective: To evaluate the predictive value of conventional criteria for identifying surgically unresectable disease among patients with ovarian cancer undergoing initial operative intervention at tertiary referral centers employing a so-called aggressive approach to surgical cytoreduction. Methods: All patients with advanced epithelial ovarian cancer undergoing primary surgery between August 1997 and August 2006 were identified. Surgical/pathological documentation of disease extent pre/post-cytoreduction was extracted from the medical record retrospectively. All patients meeting conventional criteria for unresectable disease criteria (ascites> 1000 mL, omental extension to spleen > 1 cm, parenchymal liver disease > 1cm, porta hepatis involvement > 1 cm, diaphragmatic disease > 1 cm, carcinomatosis > 1 cm, and suprarenal adenopathy > 1 cm) were selected for further study. Results: A total of 180 consecutive patients had disease meeting conventional criteria for unresectability at = 1 site(s). Optimal cytoreduction (residual disease = 1 cm) was achieved in 166 patients (92.2%). Optimal resection rates according to the most common individual unresectable disease criteria were as follows: ascites > 1000 mL = 91.3% (116/127), carcinomatosis > 1 cm = 91.0% (81/89), and splenic involvement > 1 cm = 84.9% (45/53). For patients with ascites > 1000 mL alone, optimal cytoreduction was achieved in 95.8% (46/48) of cases. Optimal resection rates according to the total number of unresectable disease sites were as follows: 1 site = 95.0% (19/20), 2 sites = 93.8% (61/65), 3 sites = 81.5% (22/27), 4 sites = 93.3% (14/15), and 5 sites = 80.0% (4/5). Conclusions: These data suggest that commonly accepted criteria of surgically unresectable disease for women with advanced ovarian cancer lack the necessary precision to guide clinical management. Pre-operative assessment of resectability should be made by an experienced surgical team prior to deferring the initial attempt at surgical cytoreduction.

KW - Cytoreductive surgery

KW - Ovarian cancer

KW - Unresectable disease

UR - http://www.scopus.com/inward/record.url?scp=38649109134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649109134&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.11.004

DO - 10.1016/j.ygyno.2007.11.004

M3 - Article

C2 - 18164380

AN - SCOPUS:38649109134

VL - 108

SP - 271

EP - 275

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -